Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 2 of 1117 for:    "Retinoschisis" OR "Retinal Degeneration" OR "X-linked juvenile retinoschisis"

Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2008 by University of Illinois at Chicago.
Recruitment status was  Recruiting
Information provided by:
University of Illinois at Chicago Identifier:
First received: July 14, 2008
Last updated: NA
Last verified: July 2008
History: No changes posted

Seven patients with X-linked retinoschisis were treated with dorzolamide and the response to this treatment was monitored using OCT. These patients were also tested for the causative gene mutation and the resultant mechanism of functional loss of retinoschisin. It was observed that a response to dorzolamide may be seen irrespective of the mechanism that leads to decrease in function of retinoschisin.

Condition Intervention Phase
Juvenile X-Linked Retinoschisis
Drug: dorzolamide
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration

Resource links provided by NLM:

Further study details as provided by University of Illinois at Chicago:

Primary Outcome Measures:
  • Decrease in the size of cystic macular lesions as tested by OCT [ Time Frame: 4-6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 15
Study Start Date: October 2005
Estimated Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Patients over the age of 18 years with juvenile X-linked retinoschisis
Drug: dorzolamide
2% dorzolamide- 1 Gtt TID


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Presence of cystic lesions on OCT testing

Exclusion Criteria:

  • Allergic reaction to sulpha containing compounds
  • Intolerance to dorzolamide
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00716586

Contact: Gerald A Fishman, MD 312.996.8939

United States, Illinois
University of Illinois Medical Center Recruiting
Chicago, Illinois, United States, 60612
Contact: Gerald A Fishman, MD    312-996-8939   
Sponsors and Collaborators
University of Illinois at Chicago
  More Information

No publications provided by University of Illinois at Chicago

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Gerald Fishman, MD, University of Illinois at Chicago Identifier: NCT00716586     History of Changes
Other Study ID Numbers: IRB-2005-0551
Study First Received: July 14, 2008
Last Updated: July 14, 2008
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Retinal Degeneration
Macular Edema
Eye Diseases
Macular Degeneration
Retinal Diseases
Antihypertensive Agents
Carbonic Anhydrase Inhibitors
Cardiovascular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on November 20, 2014